Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of NH130 citrate tablets for psychosis in Parkinson's disease
CTR20254030Phase 2Active
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing NH130 citrate with Placebo (2 arms). Primary endpoint: Change from baseline in SAPS-PD score at Day 28. Started Dec 2025; status: active.
02
Drugs
NH130
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20254030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254030.